Bio-IT World December 17, 2025
Caris Life Sciences yesterday announced that its therapeutic research arm, Caris Discovery, has entered into a multi-year collaboration and license agreement with Genentech, a member of the Roche Group.
“Caris Discovery’s approach to identifying novel drug targets leverages our biobank of more than 500,000 patients tissue samples, matched with comprehensive molecular data and clinical outcomes,” Milan Radovich, PhD, Senior Vice President and Chief Scientific Officer at Caris told Bio-IT World. “We also utilize our proprietary proteomics technologies that allow us to identify high cancer-specific proteins from patient tissues. We can tailor target discovery campaigns to almost any cancer population imaginable. This includes tumors that have developed resistance to standard-of-care therapies, where new therapeutic approaches are urgently...
Today's Sponsors
Today's Sponsor